Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more
Alkem Laboratories Limited (ALKEM) - Total Assets
Latest total assets as of September 2025: ₹202.87 Billion INR
Based on the latest financial reports, Alkem Laboratories Limited (ALKEM) holds total assets worth ₹202.87 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alkem Laboratories Limited - Total Assets Trend (2010–2025)
This chart illustrates how Alkem Laboratories Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alkem Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Alkem Laboratories Limited's total assets of ₹202.87 Billion consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹1.07 Billion | 1.7% |
| Accounts Receivable | ₹24.75 Billion | 14.0% |
| Inventory | ₹29.22 Billion | 16.5% |
| Property, Plant & Equipment | ₹28.63 Billion | 16.2% |
| Intangible Assets | ₹1.15 Billion | 0.7% |
| Goodwill | ₹4.23 Billion | 2.4% |
Asset Composition Trend (2010–2025)
This chart illustrates how Alkem Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alkem Laboratories Limited's current assets represent 61.9% of total assets in 2025, a decrease from 73.1% in 2010.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2025, down from 42.4% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 16.5% of total assets.
Alkem Laboratories Limited Competitors by Total Assets
Key competitors of Alkem Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Alkem Laboratories Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Alkem Laboratories Limited generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Alkem Laboratories Limited generates $ 12.24 in net profit.
Alkem Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.66 | 1.98 |
| Quick Ratio | 1.87 | 1.96 | 1.32 |
| Cash Ratio | 0.32 | 0.47 | 0.00 |
| Working Capital | ₹72.48 Billion | ₹ 69.32 Billion | ₹ 29.51 Billion |
Alkem Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Alkem Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.97 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 13.6% |
| Total Assets | ₹176.91 Billion |
| Market Capitalization | $2.41 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Alkem Laboratories Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alkem Laboratories Limited's assets grew by 13.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alkem Laboratories Limited (2010–2025)
The table below shows the annual total assets of Alkem Laboratories Limited from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹176.91 Billion | +13.59% |
| 2024-03-31 | ₹155.75 Billion | +13.22% |
| 2023-03-31 | ₹137.57 Billion | -2.22% |
| 2022-03-31 | ₹140.69 Billion | +22.14% |
| 2021-03-31 | ₹115.19 Billion | +15.82% |
| 2020-03-31 | ₹99.46 Billion | +21.17% |
| 2019-03-31 | ₹82.08 Billion | +7.08% |
| 2018-03-31 | ₹76.66 Billion | +16.71% |
| 2017-03-31 | ₹65.68 Billion | +18.67% |
| 2016-03-31 | ₹55.35 Billion | +4.51% |
| 2015-03-31 | ₹52.96 Billion | +21.81% |
| 2014-03-31 | ₹43.48 Billion | +7.40% |
| 2013-03-31 | ₹40.48 Billion | +27.21% |
| 2012-03-31 | ₹31.82 Billion | +22.90% |
| 2011-03-31 | ₹25.89 Billion | +66.05% |
| 2010-03-31 | ₹15.59 Billion | -- |